AR118240A1 - Compuestos útiles en la terapia del vih - Google Patents
Compuestos útiles en la terapia del vihInfo
- Publication number
- AR118240A1 AR118240A1 ARP200100588A ARP200100588A AR118240A1 AR 118240 A1 AR118240 A1 AR 118240A1 AR P200100588 A ARP200100588 A AR P200100588A AR P200100588 A ARP200100588 A AR P200100588A AR 118240 A1 AR118240 A1 AR 118240A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- useful compounds
- hiv therapy
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en la que: R¹ es: un compuesto de fórmula (2) en donde: X es seleccionado del grupo formado por NH₂, F y Cl; R⁵ se selecciona del grupo formado por el H y alquilo C₁₋₁₄; R⁶ se selecciona del grupo formado por H y -(C=O)-alquilo C₁₋₁₄; R² se selecciona del grupo que consiste en alquilo C₁₋₂₄; (CH₂)ₙ₁-O-(CH₂CH₂O)ₙ₂-(alquilo C₁₋₁₄) donde n1 y n2 son números enteros seleccionados independientemente de 1 - 4, -R⁷-NH-(C=O)-R⁸ en donde R⁷ puede ser alquilo C₁₋₁₄ y R⁸ puede ser seleccionado independientemente de H y alquilo C₁₋₁₄; -R⁹-arilo C₆₋₁₄, en donde R⁹ es un enlace o alquilo C₁₋₆; -R¹⁰-cicloalquilo C₃₋₁₄, donde R¹⁰ es un enlace o alquilo C₁₋₆; -C₁₋₂₀ alquileno-(C=O)-O-R¹¹ en donde R¹¹ puede seleccionarse entre H y alquilo C₁₋₂₀; y un compuesto de fórmula (3) y; R³ se selecciona del grupo formado por H, -(C=O)-alquilo C₁₋₂₄; -(C=O)-O-alquilo C₁₋₂₄; y cicloalquilo C₃₋₁₄ o R² y R³ se unen para formar una estructura cíclica de C₃ a C₂₈; y con la condición de que cuando R² es (alquilo C₁₋₁₄) al menos uno de R³, R⁵ y R⁶ no es H.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814316P | 2019-03-06 | 2019-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118240A1 true AR118240A1 (es) | 2021-09-22 |
Family
ID=69845479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100588A AR118240A1 (es) | 2019-03-06 | 2020-03-04 | Compuestos útiles en la terapia del vih |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20230174534A1 (es) |
| EP (1) | EP3934760A1 (es) |
| JP (1) | JP2022525013A (es) |
| KR (1) | KR20210136052A (es) |
| CN (1) | CN113811360A (es) |
| AR (1) | AR118240A1 (es) |
| AU (1) | AU2020231934B2 (es) |
| BR (1) | BR112021017604A2 (es) |
| CA (1) | CA3132112A1 (es) |
| CL (1) | CL2021002309A1 (es) |
| CO (1) | CO2021012579A2 (es) |
| CR (1) | CR20210460A (es) |
| EA (1) | EA202192433A1 (es) |
| IL (1) | IL285894A (es) |
| MA (1) | MA55200A (es) |
| MX (1) | MX2021010700A (es) |
| PE (1) | PE20212089A1 (es) |
| SG (1) | SG11202109253SA (es) |
| TW (1) | TW202102233A (es) |
| WO (1) | WO2020178767A1 (es) |
| ZA (1) | ZA202106096B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY38982A (es) | 2019-12-09 | 2021-06-30 | Viiv Healthcare Co | Composiciones farmacéuticas |
| EP4121437A1 (en) * | 2020-03-20 | 2023-01-25 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2022142477A1 (en) * | 2020-12-30 | 2022-07-07 | Southern University Of Science And Technology | Methods and modified nucleosides for treating coronavirus infections |
| AU2022211056A1 (en) * | 2021-01-25 | 2023-07-20 | Brii Biosciences, Inc. | Combination therapy for hiv with adenosine derivative and capsid inhibitors |
| WO2022182604A1 (en) * | 2021-02-23 | 2022-09-01 | Viiv Healthcare Company | Compounds useful in hiv treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| HUP0400241A2 (hu) | 2001-03-19 | 2004-06-28 | Ono Pharmaceutical Co., Ltd. | Hatóanyagként triaza-spiro[5.5]undekán-származékokat tartalmazó gyógyszerkészítmények |
| CA2502109C (en) | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| WO2015143712A1 (en) * | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| US11311545B2 (en) * | 2014-10-09 | 2022-04-26 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
| EP3212597A1 (en) * | 2014-10-31 | 2017-09-06 | Sandoz AG | Improved fluorination process |
| CN108289931B (zh) * | 2015-09-23 | 2022-10-11 | 默沙东公司 | 4’-取代的核苷逆转录酶抑制剂及其制备 |
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| WO2018085307A1 (en) * | 2016-11-03 | 2018-05-11 | Wu Laurence I | Prodrugs of clofarabine |
| US20200407393A1 (en) * | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
-
2020
- 2020-03-04 CA CA3132112A patent/CA3132112A1/en active Pending
- 2020-03-04 CR CR20210460A patent/CR20210460A/es unknown
- 2020-03-04 TW TW109107136A patent/TW202102233A/zh unknown
- 2020-03-04 JP JP2021552772A patent/JP2022525013A/ja active Pending
- 2020-03-04 WO PCT/IB2020/051878 patent/WO2020178767A1/en active Application Filing
- 2020-03-04 SG SG11202109253SA patent/SG11202109253SA/en unknown
- 2020-03-04 AR ARP200100588A patent/AR118240A1/es unknown
- 2020-03-04 KR KR1020217031465A patent/KR20210136052A/ko not_active Application Discontinuation
- 2020-03-04 AU AU2020231934A patent/AU2020231934B2/en active Active
- 2020-03-04 MX MX2021010700A patent/MX2021010700A/es unknown
- 2020-03-04 PE PE2021001461A patent/PE20212089A1/es unknown
- 2020-03-04 CN CN202080030422.7A patent/CN113811360A/zh active Pending
- 2020-03-04 BR BR112021017604A patent/BR112021017604A2/pt unknown
- 2020-03-04 MA MA055200A patent/MA55200A/fr unknown
- 2020-03-04 EA EA202192433A patent/EA202192433A1/ru unknown
- 2020-03-04 EP EP20712038.7A patent/EP3934760A1/en active Pending
- 2020-05-04 US US16/865,678 patent/US20230174534A1/en active Pending
-
2021
- 2021-06-01 US US17/335,145 patent/US20220411425A1/en not_active Abandoned
- 2021-08-24 ZA ZA2021/06096A patent/ZA202106096B/en unknown
- 2021-08-26 IL IL285894A patent/IL285894A/en unknown
- 2021-09-03 CL CL2021002309A patent/CL2021002309A1/es unknown
- 2021-09-24 CO CONC2021/0012579A patent/CO2021012579A2/es unknown
-
2023
- 2023-11-14 US US18/508,355 patent/US20240182473A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA202192433A1 (ru) | 2021-12-28 |
| CA3132112A1 (en) | 2020-09-10 |
| MX2021010700A (es) | 2021-10-01 |
| AU2020231934A8 (en) | 2022-03-24 |
| CO2021012579A2 (es) | 2021-10-20 |
| ZA202106096B (en) | 2023-03-29 |
| AU2020231934B2 (en) | 2023-04-20 |
| EP3934760A1 (en) | 2022-01-12 |
| MA55200A (fr) | 2022-01-12 |
| CN113811360A (zh) | 2021-12-17 |
| AU2020231934A1 (en) | 2021-09-23 |
| IL285894A (en) | 2021-10-31 |
| PE20212089A1 (es) | 2021-11-04 |
| US20230174534A1 (en) | 2023-06-08 |
| US20220411425A1 (en) | 2022-12-29 |
| TW202102233A (zh) | 2021-01-16 |
| US20240182473A1 (en) | 2024-06-06 |
| BR112021017604A2 (pt) | 2021-11-16 |
| KR20210136052A (ko) | 2021-11-16 |
| CR20210460A (es) | 2022-02-03 |
| JP2022525013A (ja) | 2022-05-11 |
| CL2021002309A1 (es) | 2022-09-20 |
| SG11202109253SA (en) | 2021-09-29 |
| WO2020178767A1 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118240A1 (es) | Compuestos útiles en la terapia del vih | |
| AR117139A1 (es) | Derivados de piridooxazinona como inhibidores de monoacilglicerol ligasa (magl) | |
| AR120338A1 (es) | Piridazinonas como inhibidores de parp7 | |
| AR110405A1 (es) | Compuestos | |
| AR108706A1 (es) | Derivados piperidinilo, un proceso para su preparación, y composiciones farmacéuticas que los contienen | |
| AR099788A1 (es) | Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR107249A1 (es) | Compuestos depsipeptídicos como anthelmínticos | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR101561A1 (es) | Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR115936A1 (es) | Compuestos útiles en terapia del vih | |
| AR117206A1 (es) | Derivados de octahidropirrolo[2,1-b][1,3]tiazepin-7-carboxamido útiles en la terapia para el vih y para el tratamiento del cáncer | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR114374A1 (es) | Compuestos herbicidas | |
| AR100940A1 (es) | Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados | |
| AR094944A1 (es) | Compuestos sustituidos con halógeno | |
| AR098232A1 (es) | Métodos de preparación de una formulación oftálmica y usos de la misma | |
| AR111271A1 (es) | Inhibidores dobles de magl y faah | |
| AR116392A1 (es) | Compuestos de fenoxi-piridil-pirimidina y métodos de uso | |
| AR112463A1 (es) | Derivados de propanamina para tratar el dolor y estados relacionados con dolor | |
| AR113846A1 (es) | Derivados de piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR119140A1 (es) | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas |